The rising demand for generics, increasing investments in pharmaceutical R&D, and investments in advanced manufacturing technologies by CDMOs are responsible for the growth of pharmaceutical contract development and the manufacturing market. The global pharmaceutical contract development and manufacturing market is projected to reach USD 171.3 billion by 2026 from USD 120.6 billion in 2021, at a CAGR of 7.3%
The increasing demand for biological therapies, growing focus on specialty medicines, growth in the nuclear medicines sector, and advancements in cell and gene therapies are also expected to offer market growth opportunities in the coming years
By service, the pharmaceutical contract development and manufacturing market is segmented into pharmaceutical manufacturing, biologics manufacturing, and drug development services. In 2021, the biologics manufacturing services segment accounted for the highest growth rate. The major factor driving the growth of this segment is the growing demand for vaccines and biosimilars.
By region, the pharmaceutical contract development and manufacturing market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Asia Pacific is projected to register the highest CAGR during the forecast period. This growth can be attributed to factors such as growth in the manufacturing sector, favorable government regulations, growing strategic expansions from leading companies, increasing emphasis on off-patent drugs, and the presence of a highly skilled workforce.
The pharmaceutical contract development and manufacturing market is segmented into big pharmaceutical companies, small & medium-sized pharmaceutical companies, generic pharmaceutical companies, and other end users. The small and medium-sized pharmaceutical companies segment accounted for the highest growth rate in the pharmaceutical contract development and manufacturing market in 2021. This segment's high growth can be attributed to the increasing number of emerging pharmaceutical companies that lack the in-house capabilities to manufacture and develop complex formulations and drug products.
Prominent players operating in the market are Siegfried Holding AG (Switzerland), WuXiAppTec (China), Samsung Biologics (South Korea), Boehringer Ingelheim International GmbH (Germany), Piramal Pharma Solutions (India), Vetter Pharma International GmbH (Germany), FAMAR Health Care Services (France), AbbVie Inc. (US), Aenova Group (Germany), Almac Group (UK)
- By Region: North America -50%, Europe -20%, Asia-Pacific -20%, RoW -10%
- By Designation: C-level - 25%, D-level - 20%, and Others - 55%
- By Respondent: Supply Side- 80%and Demand Side 20%
The pharmaceutical contract development and manufacturing market analysis report is a particular study of the global industry that explains the market definition, classifications, applications, engagements, and global industry trends are. This market research document offers details about market definition, market drivers, market restraints, market segmentation with respect to product usage and geographical conditions, key developments taking place in the market, competitor analysis, and the research methodology.
This study covers all the essential information regarding the world industry which helps a user to grasp the overall market. The study especially covers the supply chain analysis, the market status, growth rate, future trends, market drivers, opportunities, challenges, risks, entry barriers, sales channels, distributors, and Porter’s Five Forces Analysis. Then, the report also provides important distinguishing information regarding each of the market segments. These segments are analyzed further on different fronts such as historical performance, market size contributions, market share, and expected rate of growth.